Journal of Clinical Oncology
Articles in this Issue
Ultrasensitive ctDNA detection for relapse and response prediction in melanoma patients treated with immunotherapy.
9572 Background: Immune checkpoint inhibitors (ICIs) have markedly improved outcomes in melanoma and are now standard of c...
Terminal admission phenotype in acute myeloid leukemia: A national analysis of inpatient care intensity (NIS 2016–2023).
e23207 Background: Inpatient mortality among patients with acute myeloid leukemia (AML) remains substantial; however, term...
Embedding patient priorities into clinical research: Co-developing access, drug navigation, and communication of results within a provincial precision oncology program.
e23174 Background: Patient partners in the Personalized Onco-Genomics (POG) Program’s Patient Working Group identified thr...
Prognostic impact of digitally quantified tumor-infiltrating lymphocytes in HR+/HER2- metastatic breast cancer treated with CDK4/6 inhibitors.
1112 Background: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors plus endocrine therapy are the first-line treatment for h...
Comparative effectiveness and healthcare utilization of atezolizumab plus bevacizumab versus durvalumab plus tremelimumab in older patients with advanced hepatocellular carcinoma.
e16232 Background: Older adults constitute an increasing proportion of patients with advanced hepatocellular carcinoma (HC...
Microbiome-derived bile acids and association with dietary fiber intake to anti-tumor responses in patients with melanoma receiving immune checkpoint blockade (ICB).
9575 Background: Multiple studies have now linked high fiber diet (HFD) and outcomes with ICBs, however, the clinical acti...
Early toxicity, healthcare utilization, and survival after CAR T-cell therapy versus bispecific antibodies in DLBCL: A propensity-matched real-world analysis.
7041 Background: CD20×CD3 bispecific antibodies and CD19-directed CAR T-cell therapies are increasingly used in relapsed/r...
HA131 (hepatic arterial infusion) in combination with systemic therapy (XELOX with or without bevacizumab) as first-line treatment in gastrointestinal cancer with liver metastases: A prospective study.
e15531 Background: Hepatic arterial infusion (HAI) chemotherapy combined with systemic therapy may better control the prog...
Real-world efficacy and safety of tarlatamab in small cell lung cancer (SCLC) and extrapulmonary small cell carcinoma (EPSCC): A single-center experience.
e20127 Background: Tarlatamab, a Delta-like ligand 3 (DLL3)-targeting Bispecific T-cell Engager (BiTE), has shown signific...
Penpulimab (PD-1 inhibitor) combined with platinum-based chemotherapy as induction therapy for newly diagnosed thymic carcinoma: A multicenter, single-arm, phase II trial.
8120 Background: Our retrospective study showed that immune checkpoint inhibitors plus chemotherapy had encouraging anti-t...
Evaluating reliability of large language models for patient queries: Concordance with NCCN invasive breast cancer guideline using ChatGPT, DeepSeek, and Gemini.
e12550 Background: The increasing use of large language models (LLMs) by patients seeking healthcare information emphasize...
Impact of tumor sidedness and social determinants of health on survival in early-onset colon cancer: A SEER 2004–2022 study.
e15705 Background: Right- and left-sided colorectal cancers (CRC) differ biologically, clinically, and prognostically, but...
Histomics as an emerging avenue for oncology biomarker development: Computational Histology Artificial Intelligence (CHAI) analysis of The Cancer Genome Atlas (TCGA).
e15008 Background: Biomarkers are critical to precision oncology. The emerging modality of “histomics” is predicated upon...
High-dimensional multiplex immunofluorescence to reveal immune microenvironment remodeling in matched primary and recurrent serous ovarian cancer.
5606 Background: Recurrent serous ovarian cancer is associated with treatment resistance and poor prognosis, and changes i...
Efficacy and safety of neoadjuvant concomitant polychemotherapy (TEC) versus dose-dense regimen in luminal breast cancer.
e12662 Background: Dose-dense (DD) chemotherapy is considered standard in localized breast cancer, but has not been direct...
A phase 1/2 trial of tersolisib (LY4064809/STX-478), a pan-mutant-selective PI3Kα inhibitor (PI3Kαi), in <i>PIK3CA</i> -mutant advanced solid tumors: Updated results from PIKALO-1.
1072 Background: PI3Kαi have demonstrated clinical benefit in ~40% of patients (pts) with HR+, HER2- advanced breast cance...
Real-world treatment utilization, sequencing patterns, and healthcare resource utilization in Waldenström macroglobulinemia (WM).
e19056 Background: WM is a rare, incurable non-Hodgkin lymphoma with diverse treatment options. Given limited real-world e...
Multi-center real-world validation of the HFA-ICOS cardio-oncology risk tool in HER2-positive breast cancer patients receiving anti-HER2 therapy.
e24015 Background: The HFA-ICOS baseline cardiovascular risk stratification framework is widely recommended to guide surve...
Molecular characteristics and outcomes of early-onset pancreatic cancer: 10-year retrospective from a single-center cohort.
e16416 Background: Pancreatic cancer (PC) incidence continues to increase globally. Early-onset PC (eoPC), defined variabl...
Comparative safety and efficacy of DKRd versus DVRd regimens in multiple myeloma: A systematic review and meta-analysis.
7574 Background: The addition of anti-CD38 monoclonal antibodies to proteasome inhibitor–based triplet regimens, such as b...
Beyond fibroblast growth factor receptor 2 (FGFR2) fusions: Mutations and amplifications in intrahepatic cholangiocarcinoma.
4124 Background: FGFR2 alterations occur in 10-20% of iCCA. While FGFR-directed therapies are establis...
Percutaneous cryoablation for the treatment of extra-abdominal desmoid tumors.
11582 Background: Management of extra-abdominal desmoid tumors (DT) has evolved over the last decade, with emphasis on con...
In vivo CD19 CAR T-cell therapy (STR-P004) to induce remission in patients with autoimmune diseases (AID).
e14519 Background: Conventional CAR-T therapy is costly and complex. STARNA's STR-P004 utilizes a proprietary LNP platform...
A phase 1b, open-label, safety, tolerability, and efficacy study of HC-7366 in combination with belzutifan in patients with locally advanced (inoperable) or metastatic renal cell carcinoma.
4534 Background: HC-7366 is a novel, selective, potent activator of general control nonderepressible 2 (GCN2) kinase, regu...
Methylation pipeline to accurately detect CpG methylation status.
e15120 Background: DNA methylation is a key epigenetic modification, and aberrant methylation patterns are strongly associ...